Search

for
Search:

Research

5 / 1000+ results

Ixekizumab Improves Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis

research Ixekizumab improves physical function, quality of life, and work productivity in biologic disease-modifying antirheumatic drug-naive patients with active psoriatic arthritis

1 citations , April 2016 in “Journal of The American Academy of Dermatology”

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

Ixekizumab Shows Efficacy and Safety in Patients Who Failed Biweekly Etanercept Therapy: Analysis From UNCOVER-2, a Phase 3 Randomized Clinical Trial in Psoriasis

research Ixekizumab shows efficacy and safety in patients who failed biweekly etanercept therapy: Analysis From UNCOVER-2, a phase 3 randomized clinical trial in psoriasis

April 2016 in “Journal of The American Academy of Dermatology”

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

Anti-TNF Antibody-Induced Psoriasiform Skin Lesions in Patients with Inflammatory Bowel Disease Are Characterised by Interferon-γ-Expressing Th1 Cells and IL-17A/IL-22-Expressing Th17 Cells and Respond to Anti-IL-12/IL-23 Antibody Treatment

research Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment

278 citations , March 2013 in “Gut”

In this study, nearly 5% of anti-TNF-treated patients with IBD developed psoriasiform skin lesions, with smoking identified as a main risk factor, and ustekinumab proved highly effective in severe cases.

research IL-17 axis is a significant driver of skin inflammation in Card14 mutant pityriasis rubra pilaris model mice

February 2023 in “Research Square (Research Square)”

This study reports that a new mouse model with a CARD14 mutation successfully mimics key human PRP symptoms, and anti-IL-17A antibody significantly reduces these symptoms.